| BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL) (NCT03520920) | BeiGene | 2018-01-04 |
| SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry (NCT03452774) | Massive Bio, Inc. | 2018-01-01 |
| Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy (NCT03113422) | PrECOG, LLC. | 2017-12-27 |
| Peptide Vaccination Against PD-L1 and PD-L2 in Relapsed Follicular Lymphoma (NCT03381768) | Lars Møller Pedersen | 2017-12-12 |
| Long-term Follow-up Study of Patients Receiving CAR-T Cells (NCT03375619) | Medical College of Wisconsin | 2017-12-01 |
| A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies (NCT03329950) | Celldex Therapeutics | 2017-12-01 |
| Constitutional Genetics in Follicular Lymphoma (NCT03234140) | Hospices Civils de Lyon | 2017-11-01 |
| 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation (NCT03133221) | University of Maryland, Baltimore | 2017-10-23 |
| Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL (NCT03019666) | Masonic Cancer Center, University of Minnesota | 2017-10-18 |
| A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma (NCT03078855) | Jonathan Friedberg | 2017-09-07 |
| Nivolumab Plus Rituximab in First-line Follicular Lymphoma gr 1-3A (NCT03245021) | Dr. Eliza Hawkes | 2017-09-07 |
| TGR1202 in Relapsed and Refractory Follicular Lymphoma (NCT03178201) | Columbia University | 2017-08-20 |
| A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) (NCT03162536) | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | 2017-06-26 |
| A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL) (NCT03135262) | Hoffmann-La Roche | 2017-06-15 |
| A Study of Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (NCT03105336) | Kite, A Gilead Company | 2017-06-06 |
| High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant (NCT03128359) | City of Hope Medical Center | 2017-05-30 |
| UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep (NCT02722668) | Masonic Cancer Center, University of Minnesota | 2017-05-15 |
| Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers (NCT03037645) | Sunesis Pharmaceuticals | 2017-04-28 |
| Allo HSCT Using RIC for Hematological Diseases (NCT02661035) | Masonic Cancer Center, University of Minnesota | 2017-03-09 |
| Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies (NCT02991898) | Masonic Cancer Center, University of Minnesota | 2017-02-16 |
| Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients (NCT02877550) | Swiss Cancer Institute | 2017-02-15 |
| Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma (NCT02947347) | Pharmacyclics LLC. | 2017-01-23 |
| Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases (NCT01962636) | Masonic Cancer Center, University of Minnesota | 2016-12-01 |
| Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial Chemoimmunotherapy (NCT02966730) | Memorial Sloan Kettering Cancer Center | 2016-11-01 |
| Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers (NCT02991638) | The University of Hong Kong | 2016-11-01 |
| A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas (NCT02700022) | UNC Lineberger Comprehensive Cancer Center | 2016-10-01 |
| CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma (NCT02819583) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2016-10-01 |
| Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients (NCT02877082) | Emory University | 2016-09-01 |
| Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma (NCT02851589) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2016-07-01 |
| Identification of Hematological Malignancies and Therapy Predication Using microRNAs as a Diagnostic Tool (NCT02791217) | Assuta Medical Center | 2016-06-01 |
| Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma (NCT02793583) | TG Therapeutics, Inc. | 2016-05-25 |
| Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma (NCT02339922) | University of Washington | 2016-05-19 |
| A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma (NCT02756247) | Memorial Sloan Kettering Cancer Center | 2016-05-09 |
| Dose Optimization Study of Idelalisib in Follicular Lymphoma (NCT02536300) | Gilead Sciences | 2016-01-14 |
| Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) (NCT02631044) | Juno Therapeutics, a Subsidiary of Celgene | 2016-01-06 |
| Sequential Intranodal Immunotherapy (SIIT) Combined With Anti-PD1 (Pembrolizumab) in Follicular Lymphoma (NCT02677155) | Oslo University Hospital | 2016-01-01 |
| Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NCT02623920) | University of Arizona | 2015-12-16 |
| A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA) (NCT02576275) | SecuraBio | 2015-12-01 |
| To Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular Lymphoma (NCT02260804) | Celltrion | 2015-11-09 |
| Rituximab With or Without Ibrutinib for Patients With Advanced Follicular Lymphoma (NCT02451111) | Swiss Cancer Institute | 2015-11-06 |
| Efficacy of Consolidative Involved-site Radiotherapy for Patients With Limited-stage Follicular Lymphoma (NCT02449252) | Wuhan University | 2015-10-01 |
| Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma (NCT02258529) | Gilead Sciences | 2015-09-14 |
| A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas (NCT02401048) | Pharmacyclics LLC. | 2015-05-01 |
| GEMHDM2014 : Gem-HDM HDT and ASCT for Relapsed/ Refractory Lymphoma (NCT02295722) | AHS Cancer Control Alberta | 2015-04-01 |
| Follicular Lymphoma IV/SC Rituximab Therapy (FLIRT) (NCT02303119) | The Lymphoma Academic Research Organisation | 2015-02-02 |
| Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma (NCT02258555) | Gilead Sciences | 2015-01-01 |
| Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies (NCT02315612) | National Cancer Institute (NCI) | 2014-12-12 |
| A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL) (NCT02187861) | Hoffmann-La Roche | 2014-12-01 |
| Carfilzomib Plus Belinostat in Relapsed/Refractory NHL (NCT02142530) | Massachusetts General Hospital | 2014-10-01 |
| Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL) (NCT02242045) | Gilead Sciences | 2014-10-01 |
| A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06) (NCT02213263) | Pfizer | 2014-09-30 |
| Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma (NCT02204982) | SecuraBio | 2014-09-01 |
| BENdamustine at Elevated Dose for Relapsed Follicular Lymphoma in Intensification Therapy and Transplantation (BENEFIT) (NCT02008006) | Centre Leon Berard | 2014-07-09 |
| T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies (NCT01163201) | Masonic Cancer Center, University of Minnesota | 2014-01-01 |
| Bendamustine in Combination With Rituximab as a First-line Therapy Followed by Maintenance Therapy With Rituximab in Patients With Follicular Lymphoma (NCT02423837) | National Research Center for Hematology, Russia | 2013-12-01 |
| Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma (NCT01980654) | Pharmacyclics LLC. | 2013-12-01 |
| A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013) (NCT01953692) | Merck Sharp & Dohme LLC | 2013-11-22 |
| Phase 2 Study of Oral IXAZOMIB in Adult Participants With Relapsed and/or Refractory Follicular Lymphoma (NCT01939899) | Millennium Pharmaceuticals, Inc. | 2013-10-31 |
| A Long-term Extension Study of PCI-32765 (Ibrutinib) (NCT01804686) | Janssen Research & Development, LLC | 2013-09-09 |
| Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies (NCT01799889) | Gilead Sciences | 2013-03-14 |
| Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL (NCT01728207) | Gilead Sciences | 2013-03-01 |
| Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies (NCT01760655) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2012-12-24 |
| Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta) (NCT01662102) | Spectrum Pharmaceuticals, Inc | 2012-12-11 |
| A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (NCT01796171) | Nordic Nanovector | 2012-12-01 |
| A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL) (NCT01500538) | Peter MacCallum Cancer Centre, Australia | 2012-10-01 |
| A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) (NCT01691898) | Genentech, Inc. | 2012-09-27 |
| CD180 Overexpression in Follicular Lymphoma (NCT02978898) | Hospices Civils de Lyon | 2012-06-01 |
| Double Cord Versus Haploidentical (BMT CTN 1101) (NCT01597778) | Medical College of Wisconsin | 2012-06-01 |
| A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma (NCT01650701) | The Lymphoma Academic Research Organisation | 2012-02-01 |
| Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma (NCT01476787) | Celgene | 2011-12-29 |
| GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL) (NCT01419665) | Sandoz | 2011-12-01 |
| Study of MK-8808 for Participants With Follicular Lymphoma (MK-8808-001) (NCT01370694) | Merck Sharp & Dohme LLC | 2011-08-19 |
| Trial of Low-Dose Methotrexate and I 131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular Lymphoma (NCT01389076) | University of Michigan Rogel Cancer Center | 2011-07-01 |
| Imexon for Relapsed Follicular and Aggressive Lymphomas (NCT01314014) | University of Rochester | 2011-05-01 |
| Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas (NCT01282424) | Gilead Sciences | 2011-03-18 |
| Rituximab and Autologous Effector Lymphocytes in Non-Hodgkin Follicular Lymphoma in Response to First Line Chemotherapy (NCT01329354) | Clinica Universidad de Navarra, Universidad de Navarra | 2011-03-01 |
| BRIEF Bendamustine and Rituximab In Elderly Follicular (NCT01313611) | The Lymphoma Academic Research Organisation | 2011-02-01 |
| Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Rituximab-refractory Follicular Lymphoma (NCT01275209) | Novartis Pharmaceuticals | 2011-02-01 |
| Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma (NCT01306643) | Gilead Sciences | 2011-02-01 |
| Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma (NCT01239394) | Massachusetts General Hospital | 2010-12-01 |
| Revlimid Dose 25 mg in Association With (R-CHOP) in the Treatment Follicular Lymphoma (NCT01393756) | The Lymphoma Academic Research Organisation | 2010-12-01 |
| Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular Lymphoma (NCT01147393) | Weill Medical College of Cornell University | 2010-10-01 |
| Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma (NCT00992446) | Fred Hutchinson Cancer Center | 2010-09-02 |
| First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers (NCT01120457) | Bristol-Myers Squibb | 2010-08-01 |
| Lenalidomide Therapy In Previously Untreated, Advanced Stage Follicular Lymphoma (NCT01180569) | Memorial Sloan Kettering Cancer Center | 2010-08-01 |
| Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia (NCT01109069) | Pharmacyclics LLC. | 2010-06-01 |
| Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma (NCT01460602) | Louisiana State University Health Sciences Center Shreveport | 2010-05-01 |
| Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma (NCT01118845) | SymBio Pharmaceuticals | 2010-04-01 |
| Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma (NCT01121757) | Duke University | 2010-04-01 |
| Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell Lymphoma (NCT01078142) | Georg Hess, MD | 2010-02-02 |
| Phase II Cancer Vaccine Trial for Patients With Follicular Lymphoma (NCT01926639) | Oslo University Hospital | 2009-10-01 |
| Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZL (NCT00772668) | University of Miami | 2009-09-25 |
| Non-Interventional Study to Examine Rituximab Treatment in Follicular Lymphoma Participants (NCT02536664) | Hoffmann-La Roche | 2009-09-01 |
| Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With Rituximab (NCT00850499) | Millennium Pharmaceuticals, Inc. | 2009-09-01 |
| Brief Chemoimmunotherapy With R+B+M Followed by R in Elderly Patients Advanced Stage Untreated Follicular Lymphoma (NCT01523860) | Fondazione Italiana Linfomi - ETS | 2009-06-01 |
| Study of Repeat Intranodal Injections of Ad-ISF35 (NCT00942409) | Januario Castro, M.D. | 2009-06-01 |
| Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular Lymphoma (NCT00901927) | M.D. Anderson Cancer Center | 2009-05-01 |
| Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant (NCT00880815) | M.D. Anderson Cancer Center | 2009-02-17 |
| Use of a Patient Preferences Shared Decision-Making Encounter Tool in Clinical Practice for Patients With DLBCL and FL (NCT04160442) | Carevive Systems, Inc. | 2009-01-16 |
| Lenalidomide and R-CHOP in B-cell Lymphoma (NCT00901615) | Lymphoma Study Association | 2009-01-06 |